Howard Stern TRT: What He Said About Testosterone Replacement Therapy

What Howard Stern Has Said About Taking TRT

Howard Stern has acknowledged using testosterone replacement therapy during conversations on his SiriusXM show, framing it as one component of a broader health regimen he follows as a man in his late sixties and early seventies. His comments have been matter-of-fact rather than promotional. He has described noticing improvements in energy and general wellbeing after starting the therapy, consistent with what men with low baseline testosterone commonly report in clinical settings.

These disclosures are journalistic in origin. No formal press release or medical record has been published. Stern's statements are drawn from on-air discussions and interviews, and any connection to a specific underlying diagnosis is inference, not confirmed clinical fact.

The Tone of His Disclosure

Stern has generally discussed TRT the way he discusses other aspects of his health, including his diet, exercise habits, and mental health work. He has not described it as a performance-enhancing drug or framed it as something he takes to look younger. His characterization has been closer to "this is something my doctor recommended" than anything resembling endorsement of a lifestyle trend.

That distinction matters clinically. TRT prescribed for confirmed hypogonadism sits in a different regulatory and ethical category from testosterone used to optimize performance in men with normal baseline levels.

What He Has Not Said

Stern has not publicly named a specific testosterone product, dose, or delivery method. He has not disclosed a baseline testosterone level or described the diagnostic workup that preceded his prescription. Any claim beyond "Stern said he takes TRT" should be treated as speculation.

What Is TRT and Who Qualifies for It

Testosterone replacement therapy is a prescription treatment for male hypogonadism, a condition in which the testes produce insufficient testosterone. The Endocrine Society's 2018 clinical practice guideline defines biochemical hypogonadism as a total testosterone concentration below 300 ng/dL confirmed on at least two morning blood draws, combined with signs and symptoms such as low libido, fatigue, reduced muscle mass, or depressed mood. [1]

The guideline states: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels." [1] This language reflects decades of concern about over-prescribing TRT to men who have normal aging-related testosterone decline but not true hypogonadism.

Prevalence and Diagnosis

Population data from the European Male Aging Study (N=3,369) found that symptomatic late-onset hypogonadism, defined by both biochemical and symptomatic criteria, affected approximately 2.1% of men aged 40 to 79. [2] Among men over 70, that figure rose toward 5.1%. [2] In the United States, estimates suggest 4 to 5 million men have low testosterone, though far fewer meet the full diagnostic threshold for treatment. [3]

A single low testosterone reading is not sufficient for a prescription. Secondary causes including obesity, obstructive sleep apnea, opioid use, and hypothyroidism must be ruled out first, because correcting the underlying condition may normalize testosterone without TRT. [1]

Delivery Methods Commonly Prescribed

The most widely used TRT formulations in the United States include:

• Testosterone cypionate or enanthate injection: 100 to 200 mg intramuscularly every 7 to 14 days, or smaller weekly subcutaneous doses for steadier levels
• Topical 1% gel (AndroGel, Testim): 50 to 100 mg applied daily to shoulders or abdomen
• Transdermal patch: 2 to 4 mg released over 24 hours
• Subcutaneous pellets: 150 to 450 mg implanted every 3 to 6 months

Each method carries a different pharmacokinetic profile. Injections produce peak-and-trough fluctuations; gels provide more stable daily levels; pellets offer the longest duration between interventions. [4]

Clinical Evidence for TRT Benefits

The testosterone therapy clinical trial program that has generated the most definitive data in older men is the Testosterone Trials (TTrials), a coordinated set of seven double-blind, placebo-controlled trials in men aged 65 and older with confirmed low testosterone (below 275 ng/dL) and at least one clinical symptom. [5]

Sexual Function and Libido

The Sexual Function Trial (N=470) within the TTrials found that testosterone gel (targeting levels of 500 to 1,000 ng/dL) improved sexual desire, erectile function, and sexual activity compared to placebo, with a mean improvement of 0.58 points on the PDAS Desire subscale (P<0.001). [5] Improvement in sexual activity was roughly 1.3 encounters per month greater than placebo. [5]

Physical Performance and Muscle Mass

The Physical Function Trial found that testosterone increased leg press strength by a mean of 20.4 kg versus 12.1 kg in the placebo group, though the primary endpoint of a 6-meter-per-second walking speed improvement was not met. [5] Lean mass increased by 1.6 kg more in the testosterone group than placebo (P<0.001). [5]

Mood and Energy

The TTrials Vitality Trial showed a statistically significant improvement in energy and fatigue as measured by the FACIT-Fatigue score: men on testosterone gained 2.41 points vs. 0.39 points on placebo (P = 0.009). [5] The effect on depressive symptoms was smaller and did not reach significance on all measures, a finding consistent with meta-analytic data suggesting testosterone has modest antidepressant effects in men with comorbid hypogonadism. [6]

Cardiovascular Safety: The TRAVERSE Trial

For years the cardiovascular safety of TRT was contested. A 2010 trial published in the New England Journal of Medicine was halted early after a higher rate of cardiac events was observed in the testosterone group, though the trial was small (N=209) and enrolled men with high baseline cardiovascular risk. [7]

The TRAVERSE trial (N=5,204) was designed specifically to resolve this question. It enrolled men aged 45 to 80 with hypogonadism and either pre-existing cardiovascular disease or high cardiovascular risk, randomizing them to testosterone gel 1.62% or placebo for a mean of 22 months. [8]

The primary cardiovascular endpoint (MACE: death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of placebo (HR 0.96, 95% CI 0.78 to 1.17), meeting the pre-specified non-inferiority margin. [8] TRT did not increase major cardiovascular events in this high-risk population.

The trial did find higher rates of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone group. [8] These findings do not eliminate cardiovascular concerns entirely, and clinicians prescribing TRT to men with pre-existing arrhythmia risk must weigh them directly.

The FDA updated the testosterone prescribing label in 2015 to require a warning about potential cardiovascular risks, specifically noting the absence of established safety data for use in men with age-related testosterone decline alone. [9]

Risks, Monitoring, and What Responsible TRT Management Looks Like

TRT is not a risk-free intervention. The major adverse effects with documented clinical evidence include:

• Erythrocytosis (elevated hematocrit): Occurs in up to 20% of men on injectable testosterone; a hematocrit above 54% requires dose reduction or temporary discontinuation to reduce thrombosis risk. [1]
• Suppression of spermatogenesis: Exogenous testosterone suppresses LH and FSH, effectively halting sperm production. Men who wish to preserve fertility should not use TRT without discussing alternatives such as clomiphene citrate or human chorionic gonadotropin (hCG). [1]
• Sleep apnea exacerbation: Testosterone may worsen pre-existing obstructive sleep apnea. [4]
• Prostate effects: TRT is contraindicated in men with known or suspected prostate cancer. PSA should be measured at baseline and at 3 to 6 months. An increase of more than 1.4 ng/mL above baseline within 12 months warrants urology referral. [1]

The Endocrine Society recommends monitoring total testosterone levels 3 to 6 months after starting therapy, targeting mid-normal range (400 to 700 ng/dL for most formulations). [1] Hematocrit, PSA, and a bone density assessment at baseline (in men with osteoporosis risk) round out standard surveillance. [1]

Practical Monitoring Schedule

| Timepoint | Tests | |---|---| | Baseline | Total T (x2 morning), LH, FSH, CBC, PSA, lipids, metabolic panel | | 3 months | Total T (trough for injections), hematocrit, PSA | | 6 months | Total T, hematocrit, PSA, lipids | | Annually | All of the above, plus bone density if indicated |

Why Public Figures Discussing TRT Matters Clinically

When a widely recognized figure mentions a medical treatment on a platform reaching millions of listeners, prescription patterns respond. A 2013 analysis published in JAMA Internal Medicine found that direct-to-consumer advertising of testosterone products was associated with a nearly threefold increase in testosterone testing and prescribing from 2001 to 2011, with prescriptions rising even in men who had not had a testosterone measurement. [10]

Stern's disclosure carries less commercial intent than a pharmaceutical advertisement, but the effect on listener awareness is real. Men who hear that someone they admire takes TRT may be more likely to ask their own physician about it. That can be a positive outcome if it prompts appropriate testing in men with genuine symptoms. The risk is that some men pursue TRT without the diagnostic workup that distinguishes true hypogonadism from normal aging or reversible secondary causes.

The Difference Between Hypogonadism and "Low-Normal" Testosterone

Testosterone levels decline roughly 1% to 2% per year after age 30 in healthy men. [11] A 70-year-old man may have a total testosterone of 320 ng/dL, technically above the 300 ng/dL diagnostic threshold, without meeting criteria for treatment. Current Endocrine Society guidance explicitly discourages treating men whose testosterone is in the low-normal range but who lack symptoms. [1]

This distinction is the central clinical nuance that often gets lost in celebrity-driven coverage of TRT. A confirmed prescription, as Stern appears to have, is different from self-administered testosterone purchased outside of a medical relationship.

Age-Related Decline vs. Pathological Hypogonadism

The Baltimore Longitudinal Study of Aging found that the prevalence of a total testosterone below 325 ng/dL rose from 20% in men in their 60s to 50% in men in their 80s. [12] But low testosterone measured in a single draw does not equal a clinical diagnosis. Illness, stress, poor sleep, and obesity all suppress testosterone acutely, and a repeat morning measurement after addressing those factors frequently shows recovery. [12]

TRT in the Context of a Broader Health Approach

Stern has described a health-focused lifestyle that includes a disciplined diet, regular cardiovascular exercise, and attention to sleep. Each of those behaviors independently affects testosterone. A 2016 randomized trial (N=291) published in Obesity found that a 10% reduction in body weight via diet and exercise raised total testosterone by a mean of 2.9 nmol/L (approximately 84 ng/dL) in obese men without TRT. [13]

This does not mean lifestyle changes replace TRT in men with true hypogonadism. It means lifestyle optimization is a first-line recommendation before or alongside TRT initiation, and the two are additive. Stern's reported combination of TRT with a healthy lifestyle reflects what clinical guidance supports: TRT works better in men who are also exercising and managing weight. [1]

How TRT Is Prescribed Through Telehealth

Since 2020, telehealth-based TRT prescribing has expanded considerably. A man can now complete a home blood draw, consult with a licensed prescriber via video, and receive testosterone shipped to his home, all without an in-person visit. This model offers genuine access advantages for men in underserved areas or with scheduling constraints.

The clinical floor for responsible telehealth TRT prescribing is the same as for in-person care: two confirmed low morning testosterone measurements, a symptom assessment, exclusion of secondary causes, PSA and hematocrit at baseline, and a plan for ongoing monitoring. Platforms that skip these steps are not providing guideline-concordant care.

The FDA classifies testosterone as a Schedule III controlled substance. [9] Prescriptions require a valid prescriber-patient relationship and cannot be issued solely on the basis of a symptom questionnaire.